# Probiotics in Preterm Infants

## Sites where Local Guideline applies
- Neonatal Intensive Care Unit JHCH.

## This Local Guideline applies to:
1. Adults
2. Children up to 16 years
3. Neonates – less than 29 days

## Target audience
- NICU clinical staff, who provide care to neonatal patients

## Description
- Provides clinical staff in NICU information about the benefits of probiotics in preterm infants to prevent necrotising enterocolitis.

## Keywords
- Bifidobacteria, immunity, Lactobacilli, live micro-organisms, NEC-Necrotising Enterocolitis, preterm, probiotics, JHCH, NICU

## Document registration number
- JHCH_NICU_09.04

## Replaces existing document?
- Yes

## Related Legislation, Australian Standard, NSW Ministry of Health Policy Directive or Guideline, National Safety and Quality Health Service Standard (NSQHSS) and/or other, HNE Health Document, Professional Guideline, Code of Practice or Ethics:
- NSW Health Policy Directive 2014_036 Clinical Procedure Safety

## Prerequisites (if required)
- N/A

## Local Guideline note
- This document reflects what is currently regarded as safe and appropriate practice. The guideline section does not replace the need for the application of clinical judgment in respect to each individual patient but the procedure/s requires mandatory compliance. If staff believe that the procedure/s should not apply in a particular clinical situation they must seek advice from their unit manager/delegate and document the variance in the patients’ health record.

## Position responsible for the Local Guideline and authorised by
- Pat Marks. General Manager / Director of Nursing CYPFS

## Contact person
- Jennifer Ormsby NICU Guideline Coordinator NICU JHCH

## Contact details
- [Jennifer.Ormsby@hnehealth.nsw.gov.au](mailto:Jennifer.Ormsby@hnehealth.nsw.gov.au)
- Phone 02 4985 5304

## Date authorised
- 28/09/2016

## This document contains advice on therapeutics
- Yes
  - Approval gained from Local Quality Use of Medicines Committee on Oct 16

## Issue date
- 28/09/2016

## Review date
- December 2018

RISK STATEMENT

This local guideline has been developed to provide guidance and information for clinical staff in NICU for probiotic administration in the preterm infant. It ensures that the risks of harm to the infants whilst caring for an infant receiving probiotics are identified and managed.

Any unplanned event resulting in, or with the potential for injury, damage or other loss to infants/staff/family as a result of this management must be reported through the Incident Information management System and managed in accordance with the Ministry of Health Policy Directive: Incident managementPD2007_061. This would include unintended injury that results in disability, death or prolonged hospital stay.

Risk Category: Clinical Care & Patient Safety;

ABBREVIATIONS & GLOSSARY

<table>
<thead>
<tr>
<th>Abbreviation/Word</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>cfu</td>
<td>Colony forming units</td>
</tr>
<tr>
<td>ELBW</td>
<td>Extremely low birth weight</td>
</tr>
<tr>
<td>NEC</td>
<td>Necrotising Enterocolitis</td>
</tr>
<tr>
<td>PROPREMS</td>
<td>Trial for administration of probiotics that confirmed benefits of administration in preterm infants</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomised control trial</td>
</tr>
<tr>
<td>SAS /TGA</td>
<td>Special Access Scheme/Therapeutic Goods Administration</td>
</tr>
<tr>
<td>TLR4</td>
<td>Immune system receptor</td>
</tr>
</tbody>
</table>

OUTCOMES

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>The preterm infant will receive probiotics to prevent NEC</td>
</tr>
<tr>
<td>2</td>
<td>Parents will be fully informed of the advantages of probiotics and receive fact sheet prior to consenting to treatment</td>
</tr>
<tr>
<td>3</td>
<td>Probiotics will be stored safely in fridge 2-8°C at all times</td>
</tr>
</tbody>
</table>

Guideline Title - One Page Summary and Checklist

(Ctrl+Click on Coloured words to jump to that section)

Background

Benefits of Probiotics in the preterm neonates

Selection of probiotic strains

Optimal dose for probiotic supplementation
Practical issues

Choice of probiotic preparation for NICU, JHCH

Who is eligible to receive probiotics?

Parental Consent

When to Start?

Dose

Storage and administration of probiotics

When to stop?

Potential risks of using probiotics

References

Appendix 1 Parent Information and Consent Form

Appendix 2 Consent Form

Appendix 3 Guideline for Infloran administration

Appendix 4 Guideline for B. breve M-16V preparation and administration

GUIDELINE

This Guideline does not replace the need for the application of clinical judgment in respect to each individual patient.

Guideline for use of probiotics in preterm neonates

Background:

Necrotising enterocolitis (NEC) is the commonest and potentially disastrous gastrointestinal surgical emergency in preterm neonates. The incidence of NEC for neonates born at less than 32 weeks gestation in the neonatal intensive care unit at JHCH has been ~2.4% over the past 10 years (~10% for neonates <28 weeks gestation)¹. The mortality related to NEC requiring surgical intervention has been over 50% and is much higher in extremely low birth weight (ELBW, <1000g birth weight) neonates in the JHCH cohort.

The morbidity of definite NEC is significant and includes prolonged hospitalisation, survival with short bowel syndrome, and long term neurodevelopmental impairment, especially in extremely preterm (Gestation < 28 weeks) neonates needing surgery for the illness. Considering the complications and prolonged hospital stay associated with definite NEC, the economic burden of the illness is also significant ²-⁴. Preventing NEC is therefore a priority in the support of the very preterm infant.
Benefits of probiotics in preterm neonates:  

The intestine of the normally delivered term, breastfed infant is rapidly colonized with a number of probiotic organisms; in particular Bifidobacteria and Lactobacilli; however, the precise pattern and species involved differ around the world. In contrast, the preterm newborn intestine tends to be colonized by different microorganisms, predominantly coliforms, enterococci, and other bacteroid species, with much inter-individual variation.

Probiotics are “live micro-organisms which when administered in adequate amounts confer a health benefit on the host.” Probiotics may prevent NEC by

- promoting colonisation of the gut with beneficial organisms,
- preventing colonisation by pathogens,
- improving the maturity and function of gut mucosal barrier, and
- by modulating the immune system (e.g. TLR4 receptor, nuclear factor-kB and inflammatory cytokines) to the advantage of the host.

Administration of probiotic organisms as a means of preventing NEC is biologically feasible, is supported by extensive published clinical evidence, and has a clearly beneficial risk-benefit balance. There are now >22 randomized controlled trials (RCTs) of probiotic preparations in preterm infants, enrolling >5500 infants. Systematic reviews of these trials have documented up to 50% reduction in NEC and 30% reduction in all-cause mortality with the routine use of probiotics in high-risk preterm infants. Further subgroup analysis of the data from the systematic reviews and from the PROPREMS trial confirm that these same benefits hold true even in populations with high breast feeding rates and a low baseline incidence of NEC.

Individual experts and the recently updated Cochrane Review on the subject have commented that based on current evidence, a change in practice favoring routine probiotic supplementation in preterm neonates is justified. Subgroup analyses have reported trends suggesting that a mixture of different organisms may be more effective than a single species.

Selection of probiotic strains

There are many different mechanisms producing the benefits of probiotics and there are also strain-specific effects. Bifidobacteria and lactobacilli are the species of choice in probiotics, given the evolution of the gut flora in preterm neonates. Bifidobacteria are the dominant strains in infancy, and the combination of lactobacilli and bifidobacteria is known to promote the growth of indigenous lactic-acid bacteria (bifidogenic effect) by formation of short-chain fatty acids as a product of the fermentation process.

Evidence indicates that colonisation as well as efficacy from use of a multistrain or multispecies probiotic could be more consistent than that of a monostrain probiotic. Experts in the field have recommended that it may be better to avoid untested combinations and reasonable to use probiotic products that have previously been shown to be effective in RCTs, provided that there has been no change or compromise in the manufacturing technique.
Optimal dose for probiotic supplementation

An optimal mass or dose is essential for any probiotic strain to survive and colonise the gut. Evidence indicates that to be functional, probiotics have to be viable and in sufficient dosage levels, typically $10^6$ to $10^7$ colony-forming units (cfu)/g of product\textsuperscript{18}. Based on the median dose used in the RCTs in preterm neonates it has been suggested that a daily dose of up to $3 \times 10^9$ cfu/day may be appropriate and safe for neonates of less than 32 weeks gestation.

Practical issues

Assurance of good manufacturing practices is important. Probiotics are live microorganisms and are sensitive to oxygen, moisture and heat. Their production and packaging should therefore involve limiting their exposure to oxygen by using barrier packages and eliminating oxygen by flushing with nitrogen. Refrigeration is important to protect the product from significant temperature fluctuations.

Choice of probiotic preparation for NICU, JHCH

Infolan\textsuperscript{®} (Desma Health Care, Switzerland), 250mg capsules, containing the probiotic bacteria Lactobacillus Acidophilus and Bifidobacterium Bifidum – 1 billion cfu each, tested in over 400 neonates in RCTs\textsuperscript{9, 10} and meeting all of the above recommendations is one such product currently available in Australia from Symbion Pty Ltd, through the SAS (Special Access scheme) under the authorised prescriber pathway.

Bb M-16V (Morinaga Industries, Japan) available as sachets containing probiotic bacteria Bifidobacterium breve up to 5 billion cfu per sachet is another such product. It has been tested for safety\textsuperscript{199} and has been shown to be effective in prevention of NEC and mortality in neonates.\textsuperscript{20, 21}

Who is eligible to receive probiotics?

1. Gestation up to 31 weeks and 6 days or birth weight < 1500 grams
2. On enteral feeds (amount $\geq$ 1ml given 2\textsuperscript{nd} hourly)
3. Informed, written parental consent (as per Australian TGA requirements under the authorised prescriber pathway)

Exclusion criteria:
1. Major gastrointestinal malformation
2. Lack of informed parental consent
3. Contraindications for enteral feeds
4. Life threatening illness/condition
Parental consent:

A determination will be made on ward rounds if a preterm neonate meets eligibility criteria for probiotic supplementation. Information sheet will be given to parent/s.

Once written parental consent has been obtained, the specific probiotic name, & dose should be documented in the neonatal medication chart by junior medical staff or NPs; however, this needs to be counter-signed by a neonatologist/ neonatal fellow with authorised prescription rights.

Ethics approved Information sheet and consent form are kept in the “Probiotic Folder” in the ICU side-room. The signed consent form should be filed in the patient charts.

When to start?

Because of the importance of early establishment of commensal flora in preterm neonates\(^\text{14}\), the probiotic supplementation should be started as early as possible before pathogens colonise, or antibiotics destroy the prevailing commensals. Most of the investigators in the trials reported to date have started the probiotic supplementation when the neonates were ready for enteral feeds.

Dose:

2-3 billion cfu of probiotic bacteria per day, as a single dose, reconstituted with 1-2 mls of breast milk or formula or sterile water (See Appendix 3 and 4)

Storage and Administration of Probiotics:

The probiotic (Infloran capsules or Bb M-16V sachets) should be stored in the drug fridge (at 2 to 8º C). Probiotics should be administered with routine feeds and should be dissolved in 1-2 ml of milk by the nursing staff looking after the baby at the bedside. The resultant solution should then be administered immediately via a gastric tube. It is recommended to use appropriate PPE as per unit guidelines.

When to stop?

Temporary withholding of probiotics

- Administration of the probiotic supplementation should be stopped during periods when the enteral feeds are stopped (e.g. severe sepsis, critical illness and NEC) at the discretion of the attending neonatologist. Probiotic supplements should be recommenced 24 hrs after restarting feeds.
Ceasing probiotics

- Probiotics will be ceased at any time the parents wish to withdraw consent for any reason.

- Based on available evidence from RCTs and the inverse relation of gestational age with NEC and all-cause mortality, supplementation should be stopped after reaching the corrected gestational age of 36 weeks (or discharge, whichever occurs earlier), when the risk of these adverse outcomes is minimal.

- For infants who are transferred out of the NICU, JHCH, prior to 36 weeks completed gestation, follow the plan below provided the accepting hospital has agreed to continue the probiotic administration.
  - A 2 week supply of probiotics - box to be labelled appropriately with the patient’s MRN with appropriate cold chain maintenance (in an esky along with frozen EBM could be appropriate)
  - This should be accompanied with a medication chart with current probiotic prescribed for the appropriate duration, signed by the discharging Neonatologist
  - Also, attach the brief guide on how to administer Infloran® for the nursing staff at the accepting hospital (please see Appendix 3 & 4)

Potential risks of using probiotics:

The administration of live bacteria to immuno-compromised patients such as the very preterm infant cannot be taken lightly. Cases of probiotic-associated bacterial sepsis that have been reported have mostly been secondary to lactobacilli; 4 cases have been reported in young children, and all cases have been mild and easily treated. Most of these cases have involved children with congenital intestinal anomalies. Bifidobacteria has been reported as causing sepsis in a newborn infant; a relatively mild illness occurred in an infant after surgery for omphalocele.

An extensive review of available medical literature has concluded that “Current evidence suggests that the risk of infection with probiotic lactobacilli or bifidobacterium is similar to that of infection with commensal strains, and that consumption of such products presents a negligible risk to consumers, including immuno-compromised hosts”\(^\text{19}\). Furthermore, in the large number of published RCTs, now enrolling >5500 preterm infants, no cases of sepsis with probiotic organisms have been reported\(^8\).
References


FEEDBACK
Any feedback on this document should be sent to the Contact Officer listed on the front page.

AUTHOR: Javeed Travadi Neonatologist NICU JHCH

REVIEWERS: Denise Kinross CNC newborn Services
Rebecca Glover Neonatologist NICU JHCH
Paul Craven Neonatologist NICU JHCH
Ruth Wootton CNS NICU JHCH
Michelle Jenkins Senior pharmacist JHCH
Carly Kippist Senior Clinical Pharmacist JHH

UPDATED BY: Javeed Travadi Neonatologist NICU JHCH September 2016

APPROVED: NICU Executive Management Committee
Clinical Quality & Patient care Committee
FACT SHEET

Probiotics

We understand that having a small sick baby in the nursery is not easy. We want to keep you informed about how we plan to care for your baby.

As part of your baby’s care, we suggest that your baby should be given probiotics. This will help protect your baby and improve feeding. The probiotic preparations we use are Inforan® or B. breve M-16V.

What is different about feeding babies who are born early?
Most babies, who are born early, need to be fed slowly. Some babies find digesting milk hard, and take longer than others to feed. Most babies remain very well, but a few babies become very sick with a disease called NEC – Necrotising Enterocolitis which affects the immature gut.

What can we do to try and prevent NEC?
Your choice in how you will feed your baby is important. Breast milk is the best milk for your baby. It reduces the risks of bowel problems. Even small amounts of breast milk are important for your baby. We will support and encourage you if you choose to express breast milk. If you are unable to, or choose not to express breast milk we will use the best option possible.

What are probiotics?
Probiotics are friendly gut bacteria (similar to the bacteria found in live yoghurts) that live in our gut and help to keep us healthy. They reduce the growth of harmful bacteria and help in keeping the lining of the gut healthy.

What do we know about probiotics and babies?
Probiotics for prevention of NEC have now been studied in over 5500 babies. These studies show that babies who were given probiotics had 50% less NEC and better survival. Probiotics also helped improve feeding in babies.

How will probiotics be given and for how long?
Probiotic powder will be mixed with your baby’s milk or formula. It will be given once a day. It will be continued till your baby is 36 weeks corrected age or until your baby is ready to go home.

Are there risks to my baby from getting probiotics?
Infection from the probiotics that we will use is very rare. We will watch your baby closely for this and treat quickly if he/she becomes sick. None of the 5500 babies in the studies became sick from probiotics.
Are there any risks from not getting probiotics?

From the research done so far we know that babies who do not get probiotics have a higher chance of becoming sick with NEC and dying.

Do you have a choice?

You can choose if your baby gets probiotics or not. If you choose not to give probiotics, your baby will get the same care now and in the future. It will also not affect how you are treated by the staff looking after your baby. You may also change your mind at any time and choose to stop probiotics once they have been started.

Are probiotics licensed for use in babies in Australia?

Like many medicines used in babies, the probiotic preparations Infilar® and B. breve M-16V are not licensed for use in babies in Australia. A special scheme under the Therapeutic Goods Administration (TGA) allows doctors to use medicines for special patients and conditions. Infilar® and B. breve M-16V have been approved for use by the TGA under this special scheme.

Thank you for taking the time to read this information. We hope this will help you in making the right choice for your baby. If you have any questions please talk to the nurse or doctor looking after your baby.

If you would like your baby to receive the probiotics, please sign the consent form attached.

For further information on NEC please ask for the NEC factsheet.

References


Appendix 2

Please note that consent for probiotic supplementation is voluntary and you can withdraw consent at any time with no impact on current or future care.

I ...............................................................................................................................................................
Given Name(s)                                                             Surname

have read the information explaining probiotic supplementation that is to be given to my baby
...............................................................................................................................................................

I have read and understood the information given to me. Any questions I have asked have been answered to my satisfaction. I understand that

(1) These probiotic products are not approved for marketing in Australia but its use has been approved under the provisions of section 19(5) or section 41 HC of the Therapeutic Goods Act 1989
(2) I understand that the Commonwealth can give no guarantee as to the quality, safety, and efficacy of the probiotic product (Infloran® or Bb M-16V)
(3) Treatment with these probiotics has been shown to reduce the risk of NEC in premature babies.
(4) Based on current knowledge there are no other known risks and side effects of this probiotic.
(5) It is possible that there could be unknown risks and late side effects.
(6) There are currently no alternative treatments using approved products that are available.

I confirm that the above statements have been explained to me and in this knowledge agree to administration of the probiotic product (Infloran® or Bb M-16V) to my baby.

Dated .......................................................... day of ................................................................. 20 ..........

Signature (parent/guardian)..................................................................................................................

I, ...........................................................................................................................................................
have explained the above to the signatory who stated that he/she understood the same.

Signature:
..........................................................................................................................................................

Date....................................................................................................................................................
Appendix 3 – Infloran®

Guideline is to accompany infant being transferred out of NICU, JHCH, where the accepting unit have consented to carry on with administering probiotics.

Storage:
Please store the supplied Infloran® capsules at 2°C to 8°C.

Dose:
One capsule per day, as a single daily dose

Reconstitution:
Dissolve the contents of 1 capsule of Infloran® with 1-2 mL of breast milk or formula or sterile water. Reconstitute just before administration.

Administration of Probiotics (Infloran®):

- Check dosage and frequency as per the medication chart received from NICU, JHCH. (Please follow your unit guidelines for administration of medications and appropriate checking of medications by another member of the clinical team).

- Probiotics should be administered orally or via gastric feeding tube along with routine feeds.

- The reconstituted solution should be administered immediately via a gastric tube. More mature infants who are receiving oral suck feeds may be able to receive the solution via a teat.

- It is recommended to use appropriate PPE as per your unit guidelines.
Appendix 4 – B. breve M-16V

Guideline is to accompany infant being transferred out of NICU, JHCH, where the accepting unit have consented to carry on with administering probiotics.

Storage:
B. Breve sachets are stable at room temperature and should be stored in a ‘cool dry place’. To prevent probiotic degradation at higher temperatures, JHH NICU has elected to store B. Breve sachets in the fridge (2-8°C).

Dose:
Give 2 mL of reconstituted solution, as a single daily dose (approximately 3 billion cfu)

Reconstitution:
Disperse the contents of one sachet of B. breve M-16V with 2 mL of breast milk, or formula, or sterile water; produces final volume of 3 mL solution (= 5 billion probiotic organisms)*

Reconstitute just before administration.

Administration of Probiotics (B. breve M-16V):

- Check dosage and frequency as per the medication chart received from NICU, JHCH. (Please follow your unit guidelines for administration of medications and appropriate checking of medications by another member of the clinical team).

- Probiotics should be administered orally or via gastric feeding tube along with routine feeds.

- The reconstituted solution should be administered immediately via a gastric tube. More mature infants who are receiving oral suck feeds may be able to receive the solution via a teat.

- It is recommended to use appropriate PPE as per your unit guidelines.

*NB. B. Breve packaging states that are 3 billion units/sachet, however due to probiotic degradation, manufacturers have included additional organisms to ensure there is a minimum of 3 billion units at expiry. Independent verification has concluded that each sachet contains approximately 5 billion units/sachet.